Raised lipase without abdominal pain (incidental hyperlipasaemia or hyperamylasaemia)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Raised lipase found without abdominal pain
Laboratory tests
- Serum creatinine with eGFR
- Follow-up serum lipase (once, later)if neededElevation with no cause found (normal renal function, no GLP-1 agonist): in benign pancreatic hyperenzymaemia, the elevation persists but fluctuates widely, with transient returns to normal [1,2]. One repeat test documents that the abnormality is lasting. A single repeat test: after that, no monitoring and no repeated imaging [3].
- Abdominal ultrasound, once (not a laboratory test): rule out an acinar cell pancreatic tumour, usually large.
Do not order
- Amylase: the fee schedule specifies that it "is not indicated when acute pancreatitis is suspected"; unless the prescription gives a reason, the laboratory does a lipase instead (code 1510) [12]. Lipase is preferred to total and pancreatic amylase for the diagnosis of acute pancreatitis [4].
- Testing for SPINK1 or PRSS1 mutations in isolated hyperenzymaemia: these mutations do not explain benign pancreatic hyperenzymaemia [8].
- Lipase to screen for, diagnose or monitor pancreatic cancer: pancreatic enzyme measurement has none of these roles [3]
- Pancreatic enzymes requested as routine tests, outside acute abdominal pain: they should be measured only to confirm acute pancreatitis [3]
Sources (14)
- Gullo L. Benign pancreatic hyperenzymemia. Dig Liver Dis. 2007;39(7):698-702.
- Gullo L, Lucrezio L, Calculli L, et al. Magnetic resonance cholangiopancreatography in asymptomatic pancreatic hyperenzymemia. Pancreas. 2009;38(4):396-400.
- Lévy P. Conduite à tenir devant une élévation des enzymes pancréatiques de découverte fortuite. Gastroenterol Clin Biol 2006;30:421-6.
- Leppäniemi A, Tolonen M, Tarasconi A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27.
- Masoero G, Bruno M, Gallo L, Colaferro S, Cosseddu D, Vacha GM. Increased serum pancreatic enzymes in uremia: relation with treatment modality and pancreatic involvement. Pancreas. 1996;13(4):350-5.
- Agence européenne des médicaments. Ozempic (sémaglutide) : résumé des caractéristiques du produit (information produit EPAR), rubriques 4.4 et 4.8, consulté le 11 octobre 2026.
- Agence européenne des médicaments. Mounjaro (tirzépatide) : résumé des caractéristiques du produit (information produit EPAR), rubriques 4.4 et 4.8, consulté le 11 octobre 2026.
- Gullo L, Laghi L, Migliori M, et al. SPINK1 and PRSS1 mutations in benign pancreatic hyperenzymemia. Pancreas. 2008;37(1):31-5.
- Di Leo M, Petrone MC, Zuppardo RA, et al. Pancreatic morpho-functional imaging as a diagnostic approach for chronic asymptomatic pancreatic hyperenzymemia. Dig Liver Dis. 2016;48(11):1330-1335.
- Tenner S, Vege SS, Sheth SG, Sauer B, Yang A, Conwell DL, Yadlapati RH, Gardner TB. American College of Gastroenterology Guidelines: Management of Acute Pancreatitis. Am J Gastroenterol 2024;119(3):419-437.
- National Institute for Health and Care Excellence. Pancreatitis. NICE guideline NG104, publiée le 5 septembre 2018, mise à jour le 16 décembre 2020 : chapitre Recommendations, section 1.2 (texte introductif).
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1510 (amylasémie) et 0524 (lipasémie).
- Agence européenne des médicaments. Victoza (liraglutide) : résumé des caractéristiques du produit, rubrique 4.8.
- Agence européenne des médicaments. Januvia (sitagliptine) : résumé des caractéristiques du produit, rubrique 4.8.